Latest Articles
- ArticleRandomized phase 2 trial of NP001, a novel immune regulatorSafety and early efficacy in ALSRobert G. Miller, Gilbert Block, Jonathan S. Katz, et al.April 09, 2015
- Clinical/Scientific NotesAquaporin-4–positive myelitis associated with Sjögren syndrome and colonic adenocarcinomaThomas Rossel, Anastasia Zekeridou, Francois Ochsner, et al.April 09, 2015
- ArticlePositive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasiaVincenzo Leuzzi, Roberto Micheli, Daniela D'Agnano, et al.April 09, 2015
- ArticleCritical role for prokineticin 2 in CNS autoimmunityMhamad Abou-Hamdan, Massimo Costanza, Elena Fontana, et al.April 09, 2015
- ArticleEarly CNS neurodegeneration in radiologically isolated syndromeChristina J. Azevedo, Eve Overton, Sankalpa Khadka, et al.April 09, 2015
- Clinical/Scientific NotesSimultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody–positive encephalitisJames P. Orengo, Melike Pekmezci, Bruce A.C. CreeApril 09, 2015
- Editor's CornerIdentifying targets for diagnosis, prognosis, and treatmentJosep DalmauApril 02, 2015
- ArticleClinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathySudarshini Ramanathan, Daman Langguth, Todd A. Hardy, et al.April 02, 2015
- Clinical/Scientific NotesGlial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and PsoriasisImke Metz, Sarah Traffehn, Katrin Straßburger-Krogias, et al.April 02, 2015
- ArticleThe growing spectrum of antibody-associated inflammatory brain diseases in childrenSandra Bigi, Manisha Hladio, Marinka Twilt, et al.April 02, 2015
Pages
Advertisement